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A B S T R A C T
The majority of HER2-positive breast or gastric cancers treated with T-DM1 eventually show resistance to this
agent. We compared the eﬀects of T-DM1 and ARX788, a novel anti-HER2 antibody-drug conjugate, on cell
growth and apoptosis in HER2-positive breast cancer and gastric cancer cell lines sensitive to T-DM1, gastric
cancer cell lines resistant to T-DM1, HER2-negative breast cancer cell lines, and T-DM1-resistant xenograft
models. ARX788 was eﬀective in T-DM1-resistant in vitro and in vivo models of HER2-positive breast cancer and
gastric cancer. ARX788 showed a pronounced growth inhibitory eﬀect on all ﬁve HER2-positive cell lines tested,
of which two gastric cancer cell lines had acquired resistance to T-DM1. ARX788 evoked more apoptotic events
compared to T-DM1. While JIMT-1 and RN-87 xenograft tumors progressed on T-DM1 treatment, all such tumors
responded to ARX788, and four out of the six JIMT-1 tumors and nine out of the twelve RN-87 tumors dis-
appeared during the ARX788 treatment. Mice treated with ARX788 survived longer than those treated with T-
DM1. The data support evaluation of ARX788 in patients with HER2-positive breast cancer or gastric cancer
including cancers that progress during T-DM1 therapy.
1. Introduction
The human epidermal growth factor receptor-2 (HER2) is over-
expressed in 15%–20% of human breast and gastric cancers [1–3].
Trastuzumab, a humanized monoclonal antibody targeting HER2, has
shown substantial anti-cancer eﬃcacy in clinical trials of patients with
HER2-positive breast or gastric cancer, and it is approved for the
treatment of HER2-positive early breast cancer, advanced breast cancer,
and advanced gastric cancer [4,5]. However, resistance to trastuzumab
eventually emerges in the great majority of treated patients [6–8], and,
therefore, further improvements are required in the systemic treatment
of such patients.
Antibody-drug conjugates (ADC) are designed to deliver cytotoxic
payloads speciﬁcally to cancer cells. Trastuzumab emtansine (T-DM1,
Kadcyla) is an anti-HER2 ADC, in which the monoclonal antibody,
trastuzumab, has been armed with DM1 (a derivative of maytansine)
payloads via a non-reducible thioether linker [9]. One T-DM1 molecule
delivers an average of 3.5 DM1 payloads to the target cells. Binding of
T-DM1 to cell surface HER2 receptors induces receptor-mediated in-
ternalization, which is followed by lysosomal degradation of the con-
jugate leading to intracellular release of lysine-MCC-DM1 (4-[N-mal-
eimidomethyl] cyclohexane-1-carbonyl-DM1). Intracellular DM1 is a
powerful inhibitor of the microtubule assembly causing cancer cell
death [9,10]. The U.S. Food and Drug Administration (FDA) approved
T-DM1 as monotherapy for the treatment of patients with HER2-posi-
tive advanced breast cancer in 2013 [11,12], and for the adjuvant
treatment of patients with HER2-positive early breast cancer who have
residual invasive disease after neoadjuvant taxane and trastuzumab-
based treatment in 2019 [13]. Similarly to trastuzumab, the majority of
breast cancer patients treated with T-DM1 acquire resistance to T-DM1
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[11,12]. In addition, in one randomized trial, T-DM1 was not superior
to chemotherapy in patients with HER2-positive advanced gastric
cancer [14]. Such data suggest that both primary and acquired re-
sistance to T-DM1 are common.
ARX788 is a next generation anti-HER2 ADC containing an anti-
HER2 monoclonal antibody site-speciﬁcally conjugated to Amberstatin
269 (AS269), a proprietary version of monomethyl auristatin F (MMAF)
payload, via a non-cleavable linker [15,16]. Site-speciﬁc conjugation
was performed through para-acetylphenylalanine (pAF), a non-natural
amino acid, which was incorporated into the primary sequence of the
antibody at a deﬁned site and serves as a linkable platform for con-
jugation of the payload [15]. MMAF is a potent inhibitor of tubulin
polymerization, thereby causing cell death [17].
Here we report that ARX788 shows a stronger inhibitory eﬀect than
T-DM1 on breast cancer and gastric cancer cells sensitive to T-DM1 in
vitro. In addition, ARX788 had pronounced anti-cancer eﬀects on in
vitro and in vivo models of HER2-positive breast cancer and gastric
cancer with resistance to T-DM1.
2. Materials and methods
2.1. Cell lines
The cell lines used and their origins are summarized in Table 1. The
HER2-positive gastric cancer cell line NCI-N87 (N-87), and the HER2-
negative breast cancer cell lines MCF-7 and Hs-578T were obtained
from the American Type Culture Collection (ATCC, Manassas, VA,
USA), the HER2-positive gastric cancer cell line OE-19 from the Eur-
opean Collection of Cell Culture (CAMR Centre for Applied Micro-
biology and Research, Wiltshire, UK), and the HER2-positive breast
cancer cell line JIMT-1 from the laboratory of Cancer Biology, Uni-
versity of Tampere, Finland [18]. The cell lines were cultured according
to the recommended speciﬁcations. The T-DM1-resistant HER2-positive
gastric cancer cell lines RN-87 and ROE-19 were generated in our la-
boratory by treating the N-87 and OE-19 cells, respectively, with in-
creasing concentrations of T-DM1 (Roche Ltd., Basel, Switzerland) as
described previously [19]. Authentication of the cell lines was per-
formed using a short tandem repeat analysis.
2.2. In vitro drug sensitivity assays and caspase activation
The eﬀects of T-DM1 and ARX788 (Ambrx Inc., La Jolla, CA, USA)
on the cell growth were studied using the AlamarBlue method (Thermo
Fisher Scientiﬁc, Waltham, USA). The cells were trypsinized and plated
in ﬂat-bottomed 96-well tissue culture plates. The eﬀects of T-DM1 and
ARX788 were tested at concentrations of 0.0001, 0.0006, 0.003, 0.016,
0.08, 0.4, 1, 2, and 10 μg/mL. The MCF-7 and Hs-578T breast cancer
cell lines with low HER2 expression were used as negative controls. The
numbers of viable cells were assessed after a ﬁve-day incubation by
addition of the AlamarBlue reagent (Thermo Fisher Scientiﬁc).
Fluorescence was measured with excitation at 540 nm and emission at
590 nm using a PHERAstar FS plate reader (BMG Labtech, Germany).
The ﬂuorescence of the samples was normalized to the ﬂuorescence of
the cell-free culture media. The results are presented as the percentage
of viable cells relative to the non-treated control, obtained by dividing
the ﬂuorescence of the test samples by the ﬂuorescence of the phos-
phate-buﬀered saline (PBS)-treated control samples. The dose achieving
the half-maximal (50%) inhibitory concentration (IC50) with the drugs
was calculated using the Graphpad Prism software (GraphPad Software,
San Diego, USA).
To assess the rate of apoptosis, caspase activation was measured
using the Caspase-Glo 3/7 method (Promega, Madison, USA) [20]. The
cells were trypsinized and plated in ﬂat-bottomed 96-well tissue culture
plates. After overnight culture, medium was exchanged to a medium
containing 0.0006, 0.003, 0.016, 0.08, 0.4, 1, or 2 μg/mL concentration
of either T-DM1 or ARX788. After 48 h of incubation, 100 μL of the
medium was transferred into white-walled 96-well plates, mixed with
100 μL Caspase-Glo 3/7 reagent, incubated for 30 min at RT, and the
luminescence was recorded using a PHERAstar FS plate reader (BMG
Labtech). The results are presented as luminescence units obtained after
subtracting the luminescence value from a blank reaction (without T-
DM1 or ARX788 treatment).
2.3. Immunohistochemistry
Tissue samples from xenograft tumors were ﬁxed in 4% buﬀered
formaldehyde for 24 h, processed into paraﬃn, and sectioned. For
immunohistochemistry, 4 μm sections were deparaﬃnized followed by
antigen-retrieval in a sodium citrate buﬀer (10 mM Sodium Citrate, pH
6.0) using a 2100 Antigen Retriever (Aptum Biologics Ltd.,
Southampton, UK) following the manufacturer's recommendations.
After blocking the non-speciﬁc binding, the primary antibodies anti-
HER2 (CB11, Leica Biosystems), M30 CytoDeath (Sigma-Aldrich, St.
Louis, USA), anti-ABCC1 (HPA002380, Sigma-Aldrich), anti-ABCC2
(ab3373, Abcam, Cambridge, UK), and anti-ABCG2 (BXP-21, ab3380,
Abcam) were applied at optimized concentrations, and incubated
overnight at 4 °C. The primary antibody binding was detected using a
BrightVision Poly-HRP anti mouse kit (VWR, Radnor, USA) and 3,3′-
diaminobenzidine (ImmPACT DAB, Vector Laboratories, Burlingame,
CA, USA) following the manufacturer's recommendations. The tissue
sections were counterstained with hematoxylin. HER2 expression vi-
sualized by immunohistochemistry was quantiﬁed semi-quantitatively
using a scale negative (0), weakly positive (+), moderately positive (+
+), or strongly positive (+++). M30 CytoDeath-positive apoptotic
cells were counted from a minimum of 10 randomly selected re-
presentative tumor sections using 40x magniﬁcation of the Olympus
B×50 microscope (Olympus Corporation, Tokyo, Japan). The data are
presented as the average ± standard deviation of positive cells per one
microscope ﬁeld.
2.4. Fluorescence in situ hybridization
HER2 ﬂuorescence in situ hybridization (FISH) was performed with
a fully automated staining robot (PathCom Systems, Dublin, USA) using
a ﬂuorescein labeled genomic probe and a reagent kit from the manu-
facturer (Pathcom Systems). To visualize nuclei, 0.3 μg/mL DAPI
Table 1
The cell lines investigated.
Cell line Origin HER2 status Reported sensitivity to T-DM1
OE-19 Human gastric cancer Positive [22] Sensitive [22]
ROE-19 Human gastric cancer, derived from OE-19 Positive [19] Resistant [19]
N-87 Human gastric cancer Positive [22] Sensitive [22]
RN-87 Human gastric cancer, derived from N-87 Positive [19] Resistant [19]
JIMT-1 Human breast cancer Positive [28] Sensitive [29]
MCF-7 Human breast cancer Negative [22,29] Resistant [22,29]
Hs-578T Human breast cancer Negative [23] Resistant, reported here
Abbreviation: HER2, human epidermal growth factor receptor-2.
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(Sigma-Aldrich) was used. A Zeiss Axio Imager Z2 epiﬂuorescence mi-
croscope (Carl Zeiss, Göttingen, Germany) equipped with selective ﬁl-
ters for the detection of ﬂuorescein and DAPI was used to image sam-
ples. Fluorescence images were taken using a 100X (NA = 1.3) oil
immersion objective. A total of 100 nonoverlapping tumor cells from
each sample were scored for the green signal (the copies of HER2).
2.5. Flow cytometry
Flow cytometry was performed by using an Accuri C6 Flow
Cytometer (Accuri Cytometers, Inc., Ann Arbor, USA). To assess cell
surface HER2, the cells were trypsinized and washed with 1% BSA in
PBS. HER2 receptors were labeled using an anti-HER2 primary anti-
body (9G6.10, Thermo Fisher Scientiﬁc) that does not compete with
trastuzumab for binding [21] for 30 min at 4 °C. Then the cells were
washed twice with PBS, and labeled with AlexaFluor488-goat anti-
mouse-IgG (A488-GAMIG; Jackson ImmunoResearch, West Grove,
USA) for 30 min at 4 °C. The cells were then washed twice with PBS and
ﬁxed in 1% formaldehyde.
2.6. In vivo models of drug eﬃcacy
The National Animal Experiment Board of Finland approved the
mouse experiments. Five to 8-week-old female SCID mice (C.B-17/
IcrHan Hsd-Prkdcscid, Envigo RMS B.V., Horst, The Netherlands) were
injected subcutaneously with 15 × 106 of human breast cancer cells
(JIMT-1) in 150 μL of the cell culture medium, 14 × 106 of human
gastric cancer cells (N-87), or with 20 × 106 or 26 × 106 of T-DM1-
resistant human gastric cancer cells (RN-87) in 150 μL of the cell cul-
ture medium to establish xenograft tumors. Following this, T-DM1
(5 mg/kg) or ARX788 (5 mg/kg) were administered intravenously (i.v.)
at 7-day intervals. As a control, PBS was administered intraperitoneally
(i.p.) at 7-day intervals. Tumor size was measured using a caliper, and
tumor volume was calculated using the formula Tvol = π/6 × larger
diameter × (smaller diameter)2. Mice with tumor>20 mm in any one
dimension or with tumor ulceration were sacriﬁced using CO2 inhala-
tions and cervical dislocations.
2.7. Statistical analysis
The data are expressed as the mean ± SE. Groups were compared
using the Student's t-test when the data passed the normality test.
Unpaired groups were compared with the Mann-Whitney test. Survival
was analyzed using the Kaplan-Meier method, and survival between
groups was compared with the log-rank test. Statistical calculations
were carried out using the IBM SPSS version 24 (IBM, Armonk, USA).
All P-values are 2-sided.
3. Results
3.1. ARX788 treatment inhibits the growth of T-DM1-resistant cancer cells
in vitro
The growth inhibitory eﬀects of ARX788 and T-DM1 were compared
in ﬁve HER2-positive cancer cell lines and in two control cell lines
(MCF-7, Hs-578T) without HER2 ampliﬁcation and with low levels of
HER2 expression [22,23]. ARX788 inhibited the growth of all HER2-
positive cell lines in a dose-dependent manner (Fig. 1). Compared to T-
DM1, the ARX788 treatment resulted in a smaller percentage of sur-
viving cells particularly in the T-DM1-resistant ROE-19 and RN-87
gastric cancer cell lines (Fig. 1, D&E). The 50% inhibitory concentration
(IC50) was achieved with ARX788 in all ﬁve HER2-positive cell lines,
whereas T-DM1 reached the IC50 only in the OE-19, N-87, and JIMT-
1 cell lines. In these cell lines ARX788 yielded 1.35-fold (OE-19), 3.6-
fold (N-87), and 29.35-fold (JIMT-1) greater potency compared to T-
DM1 (Fig. 1A–E). The ARX788 IC50 values on OE-19 and ROE-19 cells
(0.033 μg/mL and 0.009 μg/mL, respectively) and on N-87 and RN-
87 cells (0.01 μg/mL and 0.041 μg/mL, respectively) were roughly si-
milar, suggesting similar activity of ARX788 in the parental, T-DM1-
sensitive cells and the corresponding T-DM1-resistant cells (Fig. 1, A&D
and B&E). Neither T-DM1 nor ARX788 was eﬀective in the HER2-ne-
gative MCF-7 and Hs-578T cell lines (Fig. 1, F&G).
Next, we measured the caspase-3 and/or caspase-7 activity in the
HER2-positive cell lines JIMT-1 and RN-87 treated with T-DM1 or
ARX788 to assess apoptosis induction rate. ARX788 increased caspase-3
and/or caspase-7 activity in a dose-dependent manner and exceeded
the eﬀect of T-DM1 in both cell lines (Fig. 1, H&I).
3.2. ARX788 eliminates T-DM1-resistant RN-87 gastric cancer xenografts
in vivo and prolongs survival
The eﬀects of ARX788 and T-DM1 on the growth of RN-87 xeno-
grafts was compared in SCID mice. The RN-87 gastric cancer xenografts
expressed HER2 at similar levels as the T-DM1-sensitive parental N-87
xenografts (Supplementary Fig. 1 A&B). Tumors formed in all 14 mice
inoculated with RN-87 cell suspension within 5 days from the date of
inoculation reaching a mean tumor volume of 52.5 ± 25.0 mm3 on
day 5. On day 13 post-inoculation the mice were split into two groups,
and treated once a week with either PBS (n = 7) or T-DM1 5 mg/kg
(n = 7). No diﬀerence in the tumor growth was observed between the
PBS or T-DM1 treatments (Fig. 2). Therefore, T-DM1 treatment was
discontinued on day 22 post-inoculation in three out of the seven mice
and switched to 5 mg/kg of ARX788, while the remaining four mice
continued to receive T-DM1. All three mice treated with ARX788 fol-
lowing the T-DM1 treatment showed rapid tumor shrinkage, whereas
the four mice that continued on T-DM1 showed persistent tumor
growth. All four mice treated continuously with T-DM1 were eu-
thanized due to tumor ulceration on day 34 (2 mice) or day 40 (2 mice).
One of the three ARX788-treated mice was euthanized on day 34 and
one on day 40 in order to harvest tumor samples for histological ex-
amination. The tumor of the third ARX788-treated mouse became un-
measurable by day 40, and no tumor relapse was observed during the
follow-up time of 13 days (Fig. 2).
In the PBS control treatment group, all seven mice were switched to
either T-DM1 (5 mg/kg, n = 4) or ARX788 (5 mg/kg; n = 3) from day
22 onwards. Mice treated with ARX788 following the PBS treatment
showed a rapid tumor shrinkage, whereas mice that received T-DM1
after PBS showed persistent tumor growth (Fig. 2). Two out of the four
T-DM1-treated mice were euthanized due to tumor ulceration on day 34
and the last two on day 40. Two out of the three ARX788-treated tu-
mors became unmeasurable by day 43 and day 53, and the third tumor
treated with ARX788 shrank to 1.0 mm3 by day 53 (Fig. 2).
To further examine the eﬃcacy of ARX788 and to generate survival
data, we next inoculated T-DM1 resistant RN-87 cells into 12 SCID
mice. On day 13 post-inoculation the mice were split into two groups
and treated once a week with either T-DM1 (5 mg/kg, n = 6) or
ARX788 (5 mg/kg, n = 6). The tumors formed continued to grow in the
T-DM1-treated mice, and all these mice were euthanized due to tumor
ulceration between day 24 and day 52. ARX788-treatment led to
complete tumor regression: no measurable tumors were observed by
day 59 in these mice (Fig. 3, A). The mice treated with ARX788 sur-
vived longer as compared with the mice treated with T-DM1
(P = 0.0007; Fig. 3, B).
3.3. ARX788 treatment eliminates JIMT-1 breast cancer xenografts in vivo
and prolongs survival
Next, we compared the eﬃcacy of ARX788 and T-DM1 in a HER2-
positive breast cancer xenograft model (JIMT-1). Tumors formed in all
20 SCID mice inoculated with a JIMT-1 cell suspension by day 7 and
reached a mean tumor volume of 229.0 ± 87.5 mm3 on day 14. On
day 15 after the inoculation, the mice were split into three treatment
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groups, which were treated once a week for three weeks with either PBS
(n = 6), T-DM1 (5 mg/kg, n = 8), or ARX788 (5 mg/kg, n = 6). While
tumors treated with either PBS or T-DM1 continued to grow, rapid
tumor shrinkage was observed in the ARX788-treated group (Fig. 4, A).
Four of the six mice treated with ARX788 had no palpable tumor from
day 77 onwards. The remaining two tumors shrank from the initial size
of 381.5 mm3 and 256.4 mm3 on day 14 to 6.3 mm3 and 1.0 mm3 on
day 63, respectively, and then started to regrow reaching the size of
78.5 mm3 and 33.5 mm3 on day 91, and progressed further despite
administration of ﬁve additional doses of ARX788 (Fig. 4, A). Also in
this setting ARX788 signiﬁcantly prolonged the survival of the tumor-
bearing mice compared to T-DM1 (P = 0.0006; Fig. 4, B).
3.4. ARX788 induces apoptotic cell death in T-DM1-resistant breast cancer
and gastric cancer xenografts
Formalin-ﬁxed paraﬃn-embedded xenograft tumor sections were
stained with the M30 CytoDeath antibody to detect apoptotic cells
using immunohistochemistry. More apoptotic cells were detected in the
RN-87 gastric cancer xenografts when the treatment was switched from
T-DM1 to ARX788 than in RN-87 xenograft tumors that were con-
tinuously treated with T-DM1 (P < 0.001, Fig. 5, A&B, Supplementary
Fig. 2). Moreover, more apoptotic cells were detected in the JIMT-1
breast cancer xenografts treated with ARX788 than in tumors treated
with T-DM1 (P < 0.001; Fig. 5 D-E, Supplementary Fig. 2). Only a few
apoptotic cells were observed in the JIMT-1 tumors that progressed
during ARX788 treatment (Fig. 5 F, Supplementary Fig. 2).
Fig. 1. Eﬀect of T-DM1 and ARX788 on the growth (A-G) and caspase activity (H, I) of breast cancer and gastric cancer cells lines. The cell growth rate was assessed
with the AlamarBlue method and apoptosis with the Caspase-Glo 3/7 method.
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3.5. Loss of HER2 protein expression and HER2 gene ampliﬁcation in JIMT-
1 xenograft tumors that progressed on ARX788 treatment
JIMT-1 tumors treated continuously with T-DM1 retained their
HER2 protein expression and HER2 gene ampliﬁcation, but the two
JIMT-1 tumors that initially responded to ARX788 but later progressed
despite continued ARX788 treatment lost both HER2 protein expression
and HER2 gene ampliﬁcation (Supplementary Fig. 1 C-F and
Supplementary Fig. 3, respectively).
3.6. HER2 expression may decrease as gastric cancer cells become resistant
to T-DM1
Cell surface HER2 protein levels were quantitated using ﬂow cyto-
metry. The T-DM1-resistant RN-87 and ROE-19 cells had slightly lower
HER2 expression than their T-DM1-sensitive counterparts (N-87 and
OE-19; P = 0.006 and P = 0.008, respectively), suggesting that also
other mechanisms may contribute to resistance. As expected, MCF-7
and Hs-578T cells expressed low levels of HER2 (Fig. 6).
4. Discussion
The majority of cancer patients who respond to T-DM1 eventually
cease to respond to it [11,12]. Since patients with T-DM1-resistant
cancer have limited therapeutic options, there is an unmet medical
need to develop novel agents for HER2-positive cancers. We compared
the in vitro and in vivo eﬃcacy of ARX788, a next generation anti-HER2
ADC, to T-DM1 in a panel of breast and gastric cancer cell lines in-
cluding T-DM1 resistant cell lines. ARX788 had a more pronounced
inhibitory eﬀect on breast cancer and gastric cancer cells sensitive to T-
DM1 (N-87, and OE-19) or sensitive to higher concentrations of T-DM1
(JIMT-1) than T-DM1. Moreover, ARX788 showed a substantial anti-
cancer eﬀect in in vitromodels of gastric cancer with acquired resistance
to T-DM1 (RN-87, ROE-19). ARX788 induced caspase-3 and/or caspase-
7 activity more eﬃciently than T-DM1 indicating that ARX788 evoked a
higher rate of apoptotic cell death. Importantly, ARX788 showed a
Fig. 2. Eﬀect of T-DM1 and ARX788 on the growth
of RN-87 xenografts in SCID mice. The drug admin-
istration days are indicated with arrows below the X-
axis. On day 22 after tumor inoculation the T-DM1
treatment was switched to ARX788 in a few mice,
and PBS treatment to ARX788, or to T-DM1. On day
34, two mice continuously treated with T-DM1 and
two mice treated with T-DM1 after PBS were eu-
thanized due to ulceration of the tumor, one mouse
treated with ARX788 after T-DM1 was also eu-
thanized in order to harvest tumor samples (a).
Fig. 3. The eﬀects of T-DM1 and ARX788 administration on the growth of RN-87 xenografts (A) and survival (B) of mice. Survival was calculated from the date of
tumor cell inoculation. The drug administration days are indicated with arrows below the X-axis in panel A.
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strong anti-cancer eﬀect in the T-DM1-resistant breast cancer and gas-
tric cancer xenografts.
The cytotoxic eﬀect of T-DM1 likely depends on achieving a suﬃ-
cient intracellular concentration of its cytotoxic payload, DM1 [10].
Hence, the mechanisms that can lower the intracellular DM1 con-
centration could play a role in T-DM1 resistance. For example, down-
regulation of HER2 receptors on the cell surface might result in inter-
nalization of fewer T-DM1 molecules into the cancer cells [24], or
increased expression of ABC drug transporters may lead to eﬄux of
more DM1 from cancer cells [24,25]. In accordance with these ﬁndings,
we observed lower expression of HER2 on the T-DM1-resistant RN-87
and ROE-19 gastric cancer cells as compared to their sensitive coun-
terparts. In addition, the T-DM1-resistant RN-87 and ROE-19 cells have
higher ABC transporter expression than the sensitive N-87 and OE-
19 cells [19]. A complete loss of HER2 expression caused acquired T-
DM1-resistance in an in vitro model using JIMT-1 breast cancer cells
[26]. Here we report retained expression of HER2 in T-DM1-resistant
JIMT-1 xenografts. The mechanisms responsible for T-DM1 resistance
are still not completely understood and require further study.
We applied two treatment strategies to test ARX788 eﬃcacy on
Fig. 4. Eﬀects of phosphate buﬀered saline (PBS), T-DM1, and ARX788 on the growth of JIMT-1 xenografts (A). The drug administration days are indicated with
arrows below the X-axis. Two out of the 6 mice treated with ARX788 relapsed and progressed despite additional doses of ARX788. The remaining 4 mice treated with
ARX788 had no palpable tumor from day 77 onwards. (B) Survival of mice in the T-DM1 and ARX788 treatment groups since the date of tumor inoculation.
Fig. 5. Immunohistochemical staining to visualize the apoptotic cells in RN-87 and JIMT-1 xenograft tumors. (A, B) More apoptotic cancer cells (brown staining)
were present in RN-87 tumors whose treatment was switched from T-DM1 to ARX788 (B) than in tumors treated continuously with T-DM1 (A). (C-F) More apoptotic
cancer cells (arrows) were present in JIMT-1 tumors that responded to ARX788 (E) than in tumors treated with PBS (C) or T-DM1 (D), or in tumors that progressed on
ARX788 after an initial response (F). The scale bar = 30 μm. . (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the Web
version of this article.)
Fig. 6. HER2 expression in the cell lines studied. Flow cytometric quantiﬁcation
of cell surface HER2 content (ﬂuorescence intensity) in seven cancer cell lines.
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HER2-positive breast cancer and gastric cancer xenografts. First,
ARX788 was highly eﬀective on relatively large RN-87 xenograft tu-
mors that were previously nonresponsive to T-DM1. In this setting, a
rapid tumor shrinkage was observed when the treatment was switched
from T-DM1 to ARX788. Second, a rapid and complete tumor shrinkage
was observed in all RN-87 xenografts and in four out of six JIMT-1
xenografts when ARX788 was given to mice carrying small to moderate
size subcutaneous tumors that had not been previously treated with T-
DM1. The remaining two JIMT-1 xenograft tumors initially responded
to ARX788 treatment and showed pronounced shrinkage, but 48 days
after the treatment was discontinued both tumors progressed, and de-
spite additional ARX788 treatments these tumors continued to grow.
Notably, the ARX788 nonresponsive tumors had lost detectable HER2
protein expression in immunohistochemical analyses and showed loss
of HER2 gene ampliﬁcation in FISH, which explains the lack of response
to ARX788. Importantly, ARX788 signiﬁcantly increased survival of
mice bearing RN-87 or JIMT-1 tumors as compared to T-DM1. The anti-
tumor eﬀect of ARX788 seemed not to be dependent on the tumor size,
because rapid and complete tumor shrinkage was observed also in mice
bearing relatively large RN-87 tumors.
One T-DM1 carries on average 3.5 lysine-MCC-DM1, and one
ARX788 carries two pAF-AS269 (a derivative of monomethyl auristatin
F, MMAF) payloads [27]. Despite a lower drug to antibody ratio,
ARX788 showed superior anti-cancer eﬃcacy in our breast cancer and
gastric cancer models. The T-DM1-resistant RN-87 and ROE-19 cells
express high amounts of ABC transporters (ABCC1, ABCC2, and ABCG2)
[19], and the expression of these proteins was higher in the T-DM1-
resistant than in the T-DM1-sensitive N87 xenografts (Supplementary
Fig. 4). The inhibition of ABC transporters sensitizes the resistant cells
to T-DM1 [19] indicating that ABC transporters may play an important
role in the T-DM1-resistance of these cells. Yet, these cells were highly
sensitive to ARX788, suggesting that pAF-AS269 may be a less avid
substrate for ABCC1, ABCC2, and/or ABCG2 than lysine-MCC-DM1, the
active metabolite of T-DM1, but this hypothesis requires further study.
Neither lysine-MCC-DM1 nor MMAF can cross the cell membrane
[9,17], which may limit the bystander eﬀect of both ARX788 and T-
DM1.
In summary, we compared the anti-tumor eﬀects of T-DM1 and
ARX788, a next generation anti-HER2 ADC. ARX788 showed a stronger
inhibitory eﬀect than T-DM1 on breast and gastric cancer cells sensitive
to T-DM1 and on gastric cancer cells with acquired resistance to T-DM1
in vitro. ARX788 caused complete tumor regression of T-DM1-resistant
breast cancer and gastric cancer xenograft tumors in vivo. The results
support clinical investigation of ARX788 in patients with HER2-positive
breast cancer or gastric cancer including patients with T-DM1-resistant
HER2-positive cancer. ARX788 is currently being evaluated in a phase I
multicenter study in patients with HER2-positive breast cancer or gas-
tric cancer (NCT03255070).
Authors’ contributions
MB conceived the hypothesis, led the project, designed the experi-
mental approach, performed the experimental work, analyzed data,
coordinated the project, and drafted the manuscript together with HJ.
VLJ discussed the hypothesis, designed the experimental approach,
performed the experimental work, participated in writing the manu-
script, and supervision of AM.
AM discussed the hypothesis, designed the experimental approach,
and performed the experimental work.
JI discussed the hypothesis, designed the experimental approach,
performed the experimental work, and interpreted data.
MS discussed the hypothesis, designed the experimental approach,
and performed the experimental work.
PL discussed the hypothesis, designed the experimental approach,
interpreted data, supervised VLJ and AM, and edited manuscript.
HJ led the project, discussed the hypothesis, designed the
experimental approach, interpreted data, and drafted the manuscript
together with MB.
All authors approved the ﬁnal manuscript.
Declaration of competing interest
Heikki Joensuu is a board member of Sartar Therapeutics, has a co-
appointment at Orion Pharma, and has received fees from Orion
Pharma and Neutron Therapeutics Ltd.
Acknowledgements
We thank Ambrx Inc. for providing ARX788, and technician Mrs.
Marja Ben-Ami for her skillful help in performing the experiments. The
present study was supported by grants from the Academy of Finland,
Cancer Society of Finland, Sigrid Jusélius Foundation, Jane and Aatos
Erkko Foundation, Finnish Cancer Organizations, K. Albin Johansson
foundation, and Helsinki University Research Grants.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.canlet.2019.12.037.
References
[1] D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire, Human breast
cancer: correlation of relapse and survival with ampliﬁcation of the HER-2/neu
oncogene, Science 235 (1987) 177–182.
[2] D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong, D. Keith, W. Levin, S. Stuart,
J. Udove, A. Ullrich, Studies of the HER-2/neu proto-oncogene in human breast and
ovarian cancer, Science 244 (1989) 707–712.
[3] C. Gravalos, A. Jimeno, HER2 in gastric cancer: a new prognostic factor and a novel
therapeutic target, Ann. Oncol. 19 (2008) 1523–1529.
[4] D. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming,
W. Eiermann, J. Wolter, M. Pegram, J. Baselga, L. Norton, Use of chemotherapy
plus a monoclonal antibody against HER2 for metastatic breast cancer that over-
expresses HER2, N. Engl. J. Med. 344 (2001) 783–792.
[5] Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki,
F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle,
J. Ruschoﬀ, Y.K. Kang, G.A.T.I. To, Trastuzumab in combination with che-
motherapy versus chemotherapy alone for treatment of HER2-positive advanced
gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, ran-
domised controlled trial, Lancet 376 (2010) 687–697.
[6] R. Nahta, D. Yu, M. Hung, G. Hortobagyi, F. Esteva, Mechanisms of disease: un-
derstanding resistance to HER2-targeted therapy in human breast cancer, Nat. Clin.
Pract. Oncol. 3 (2006) 269–280.
[7] A.F. Okines, D. Cunningham, Trastuzumab: a novel standard option for patients
with HER-2-positive advanced gastric or gastro-oesophageal junction cancer, Ther.
Adv. Gastroenterol. 5 (2012) 301–318.
[8] R. Nahta, F.J. Esteva, HER2 therapy: molecular mechanisms of trastuzumab re-
sistance, Breast Cancer Res. 8 (2006) 215.
[9] G.D. Lewis Phillips, G. Li, D.L. Dugger, L.M. Crocker, K.L. Parsons, E. Mai,
W.A. Blattler, J.M. Lambert, R.V.J. Chari, R.J. Lutz, W.L.T. Wong, F.S. Jacobson,
H. Koeppen, R.H. Schwall, S.R. Kenkare-Mitra, S.D. Spencer, M.X. Sliwkowski,
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cyto-
toxic drug conjugate, Cancer Res. 68 (2008) 9280–9290.
[10] M. Barok, H. Joensuu, J. Isola, Trastuzumab emtansine: mechanisms of action and
drug resistance, Breast Cancer Res. 16 (2014) 209.
[11] S.A. Hurvitz, L. Dirix, J. Kocsis, G.V. Bianchi, J. Lu, J. Vinholes, E. Guardino,
C. Song, B. Tong, V. Ng, Y.W. Chu, E.A. Perez, Phase II randomized study of tras-
tuzumab emtansine versus trastuzumab plus docetaxel in patients with human
epidermal growth factor receptor 2-positive metastatic breast cancer, J. Clin. Oncol.
31 (2013) 1157–1163.
[12] S. Verma, D. Miles, L. Gianni, I. Krop, M. Welslau, J. Baselga, M. Pegram, D. Oh,
V. Dieras, E. Guardino, L. Fang, M. Lu, S. Olsen, K. Blackwell, Trastuzumab em-
tansine for HER2-positive advanced breast cancer, N. Engl. J. Med. 367 (2012)
1783–1791.
[13] G. von Minckwitz, C.S. Huang, M.S. Mano, S. Loibl, E.P. Mamounas, M. Untch,
N. Wolmark, P. Rastogi, A. Schneeweiss, A. Redondo, H.H. Fischer, W. Jacot,
A.K. Conlin, C. Arce-Salinas, I.L. Wapnir, C. Jackisch, M.P. DiGiovanna,
P.A. Fasching, J.P. Crown, P. Wulﬁng, Z. Shao, E. Rota Caremoli, H. Wu, L.H. Lam,
D. Tesarowski, M. Smitt, H. Douthwaite, S.M. Singel, C.E. Geyer Jr.,
K. Investigators, Trastuzumab emtansine for residual invasive HER2-positive breast
cancer, N. Engl. J. Med. 380 (2019) 617–628.
[14] P.C. Thuss-Patience, M.A. Shah, A. Ohtsu, E. Van Cutsem, J.A. Ajani, H. Castro,
W. Mansoor, H.C. Chung, G. Bodoky, K. Shitara, G.D.L. Phillips, T. van der Horst,
M.L. Harle-Yge, B.L. Althaus, Y.K. Kang, Trastuzumab emtansine versus taxane use
M. Barok, et al. Cancer Letters 473 (2020) 156–163
162
for previously treated HER2-positive locally advanced or metastatic gastric or
gastro-oesophageal junction adenocarcinoma (GATSBY): an international rando-
mised, open-label, adaptive, phase 2/3 study, Lancet Oncol. 18 (2017) 640–653.
[15] R.C. Humphreys, J. Kirtely, A. Hewit, S. Biroc, N. Knudsen, L. Skidmore, A. Wahl,
Site speciﬁc conjugation of ARX-788, an antibody drug conjugate (ADC) targeting
HER2, generates a potent and stable targeted therapeutic for multiple cancers,
Cancer Research, Proceedings of the 106th Annual Meeting of the American
Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. AACR; Cancer
Res. Philadelphia (PA) vol. 75, (2015) (15 Suppl): abstract #639.
[16] D.J. Newman, G.M. Cragg, Current status of marine-derived compounds as war-
heads in anti-tumor drug candidates, Mar. Drugs 15 (2017) 99.
[17] A.H. Staudacher, M.P. Brown, Antibody drug conjugates and bystander killing: is
antigen-dependent internalisation required? Br. J. Canc. 117 (2017) 1736–1742.
[18] M. Tanner, A. Kapanen, T. Junttila, O. Raheem, S. Grenman, J. Elo, K. Elenius,
J. Isola, Characterization of a novel cell line established from a patient with
Herceptin-resistant breast cancer, Mol. Cancer Ther. 3 (2004) 1585–1592.
[19] V. Le Joncour, A. Martins, M. Puhka, J. Isola, M. Salmikangas, P. Laakkonen,
H. Joensuu, M. Barok, A novel anti-HER2 antibody-drug conjugate XMT-1522 for
HER2-positive breast and gastric cancers resistant to trastuzumab emtansine, Mol.
Cancer Ther. 18 (2019) 1721–1730.
[20] M. Barok, M. Puhka, G. Vereb, J. Szollosi, J. Isola, H. Joensuu, Cancer-derived
exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer
cells leading to growth inhibition and caspase activation, BMC Canc. 18 (2018) 504.
[21] C.T. Chan, M.Z. Metz, S.E. Kane, Diﬀerential sensitivities of trastuzumab
(Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-
3K) and epidermal growth factor receptor (EGFR) kinase inhibitors, Breast Canc.
Res. Treat. 91 (2005) 187–201.
[22] M. Barok, M. Tanner, K. Koninki, J. Isola, Trastuzumab-DM1 is highly eﬀective in
preclinical models of HER2-positive gastric cancer, Cancer Lett. 306 (2011)
171–179.
[23] D.L. Holliday, V. Speirs, Choosing the right cell line for breast cancer research,
Breast Cancer Res. 13 (2011) 215.
[24] G. Li, J. Guo, B.Q. Shen, D.B. Yadav, M.X. Sliwkowski, L.M. Crocker, J.A. Lacap,
G.D.L. Phillips, Mechanisms of acquired resistance to trastuzumab emtansine in
breast cancer cells, Mol. Cancer Ther. 17 (2018) 1441–1453.
[25] N. Takegawa, Y. Nonagase, K. Yonesaka, K. Sakai, O. Maenishi, Y. Ogitani,
T. Tamura, K. Nishio, K. Nakagawa, J. Tsurutani, DS-8201a, a new HER2-targeting
antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor,
overcomes HER2-positive gastric cancer T-DM1 resistance, Int. J. Cancer 141
(2017) 1682–1689.
[26] Y. Endo, Y. Shen, L.A. Youssef, N. Mohan, W.J. Wu, T-DM1-resistant cells gain high
invasive activity via EGFR and integrin cooperated pathways, mAbs 10 (2018)
1003–1017.
[27] A. Beck, L. Goetsch, C. Dumontet, N. Corvaia, Strategies and challenges for the next
generation of antibody-drug conjugates, Nat. Rev. Drug Discov. 16 (2017) 315–337.
[28] M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi,
A. Kapanen, M. Tanner, G. Vereb, J. Szollosi, Trastuzumab causes antibody-de-
pendent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1
breast cancer xenografts despite intrinsic drug resistance, Mol. Cancer Ther. 6
(2007) 2065–2072.
[29] M. Barok, M. Tanner, K. Koninki, J. Isola, Trastuzumab-DM1 causes tumour growth
inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo,
Breast Cancer Res. 13 (2011) R46.
M. Barok, et al. Cancer Letters 473 (2020) 156–163
163
